The MASH Telehealth Program: Building a Liver Health Category Around the New GLP-1 Indication

MASH is the first chronic liver disease with an approved GLP-1 indication. It is not a weight loss program.

For years, the GLP-1 story in DTC telehealth has been a weight story. Patients arrived through a weight loss funnel, qualified on BMI, and retained on body composition outcomes.

The FDA's approval of semaglutide for MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced fibrosis breaks that pattern.

MASH is a chronic liver disease. The patient does not necessarily care about weight, even when weight is part of the picture. The clinical goal is not pounds; it is fibrosis stabilization and reversal. The provider review is not a body composition check; it is a liver-disease management decision. The retention story is not a scale; it is the next FibroScan.

A weight loss program that adds a MASH module is going to disappoint MASH patients and confuse weight loss patients. A MASH program needs its own intake, its own labs, its own imaging coordination, its own referral pathway, and its own clinical narrative.

This post is how to build it.

Why MASH is the right next category to build

MASH is a real category, not a marketing wedge. A few reasons it makes sense as a 2026 DTC telehealth build.

Factor	What it means
FDA-approved indication for a telehealth-prescribable drug	Removes the gray-zone problem that has shadowed off-label GLP-1 prescribing
Large underdiagnosed population	A meaningful share of adults with obesity, type 2 diabetes, or metabolic syndrome have undiagnosed fatty liver disease in some stage
Long-term care model	MASH is chronic. Patients stay in the program for years, not months
Differentiated clinical story	Liver-health framing is distinct from weight loss framing and does not depend on body composition narratives
Multiple touchpoints	Labs, imaging, provider review, follow-up, lifestyle support all repeat
Lower ad-policy friction	A liver-health program faces less platform-level scrutiny than a weight loss program
Higher clinical defensibility	A patient with documented fibrosis on a labeled drug is a defensible chart

The category also fits a quiet but important DTC trend: programs that treat actual diseases, not aesthetic outcomes. That is where the platform, regulatory, and clinical winds are blowing.

For the broader case on which programs to build next, see Telehealth Specialty Expansion: How to Decide the Next Program After GLP-1, Hair Loss, or Sexual Health.

Who actually belongs in a MASH program

The intake is where a MASH program either earns its clinical legitimacy or just becomes a weight loss program in a new costume.

The FDA-approved indication targets MASH with moderate to advanced (F2 to F3) fibrosis. That is a specific clinical population, and the intake should reflect that.

A defensible MASH intake covers:

Metabolic risk factors: type 2 diabetes, obesity, dyslipidemia, hypertension, metabolic syndrome
Hepatic history: prior abnormal LFTs, imaging findings, biopsies, hepatology consultation
Risk scoring: FIB-4 score from available labs (age, AST, ALT, platelets), NFS (NAFLD Fibrosis Score) where data permits
Symptom history: fatigue, right upper quadrant discomfort, but understanding that MASH is often asymptomatic
Comorbidities and red flags: alcohol use (above thresholds, this becomes alcohol-associated liver disease, not MASH), hepatitis B and C status, autoimmune liver disease history, hereditary conditions, medication-induced hepatic injury
Pregnancy status and contraception for women of reproductive age, given GLP-1 considerations
Prior GLP-1 exposure and tolerance

The intake should not pretend to diagnose MASH on its own. It should triage patients into one of three buckets:

Bucket	What it means	Next step
Likely candidate, ready for evaluation	Risk factors present, FIB-4 in indeterminate or high range, no red flags	Proceed to labs and imaging coordination
Possible candidate, more workup needed	Some risk factors, missing data, ambiguous history	Targeted lab panel before further evaluation
Not a candidate or refer out	Red flags, alternative liver disease, decompensation signs, advanced cirrhosis	Hepatology referral, not telehealth-managed

For the underlying intake design patterns this builds on, see Smart Branching in Intake Forms: Fewer Questions, Better Qualification and The Weight Loss Intake Form Scorecard: 12 UX Checks Before You Launch.

Fibrosis assessment without a biopsy

The diagnostic gold standard for MASH staging is liver biopsy. That is not a telehealth-feasible procedure. The realistic 2026 workflow uses non-invasive testing, which is now broadly accepted in clinical guidelines.

The two layers a DTC MASH program needs.

Layer one: laboratory-based scoring

Calculable from a basic metabolic panel and platelets that the program orders anyway.

FIB-4: validated, widely used, cheap. Indeterminate range needs further evaluation.
NFS (NAFLD Fibrosis Score): uses age, BMI, hyperglycemia status, AST, ALT, platelets, albumin.
APRI: AST-to-platelet ratio index, useful as a secondary check.
ELF test (Enhanced Liver Fibrosis): a blood-based test with three serum markers; more sensitive than FIB-4 but more expensive and requires a vendor with availability.

A reasonable default: FIB-4 on every patient at intake, ELF for patients in indeterminate FIB-4 ranges or where the clinical picture is ambiguous.

Layer two: imaging-based assessment

Imaging is the differentiator. Without it, fibrosis staging is guesswork.

Transient elastography (FibroScan): the most accessible imaging tool, available in many outpatient settings, gives a liver stiffness measurement (LSM) and a CAP score for steatosis.
MRE (magnetic resonance elastography): more accurate, less accessible, more expensive.
2D-SWE (shear wave elastography): ultrasound-based, increasingly available.

A DTC MASH program needs a real plan for getting patients to imaging. This is the part most operators underestimate. The options:

Partnerships with imaging vendor networks that already operate FibroScans
Local-affiliated hepatology or GI practices that perform elastography
Mobile or pop-up imaging vendors in some metros
For patients in low-access regions, a referral pathway to the nearest center that can do at least one elastography measurement

The program should be honest with itself: if a state or region cannot reliably get patients to imaging, the program cannot serve those patients responsibly at the F2 to F3 indication.

For the broader lab and hybrid-workflow patterns, see Telehealth Lab Workflow Design: Preventing Drop-Off Between Order, Completion, and Review and Hybrid Telehealth Workflows: How to Coordinate Labs, Pharmacies, Devices, and In-Person Referrals.

The lab cadence for a MASH program

The lab cadence is different from a weight loss GLP-1 program because the disease being treated is different.

A defensible baseline panel for a MASH evaluation:

Comprehensive metabolic panel (LFTs, glucose, kidney function, albumin)
CBC with platelets (for FIB-4)
HbA1c
Lipid panel
Hepatitis B surface antigen and core antibody, hepatitis C antibody
Iron studies (ferritin, transferrin saturation) to screen for hemochromatosis
Autoimmune panel where the clinical picture warrants (ANA, ASMA, AMA, immunoglobulins)
Thyroid function
ELF or FIB-4 calculation
For some patients, ceruloplasmin (Wilson's), alpha-1 antitrypsin

After enrollment, a sustainable cadence:

Time	Tests
Baseline	Full panel above plus FibroScan or equivalent
12 weeks	LFTs, FIB-4 recheck, treatment-tolerance check
6 months	LFTs, metabolic panel, HbA1c, FIB-4
12 months	Full re-evaluation panel plus repeat elastography
Annually thereafter	LFTs, FIB-4, elastography every 12 to 24 months by clinical judgment

This is a real chronic-disease lab program. It also justifies its own pricing, because the value to the patient is durable disease-management, not a one-time prescription.

Provider model and hepatology referral

MASH is a hepatology condition. A DTC telehealth program can serve the population, but it needs honest decisions about provider scope.

The defensible patterns:

Internal medicine, family medicine, and endocrinology providers can manage uncomplicated MASH at F2 to F3 with the right protocols
Hepatology consultation is appropriate for ambiguous cases, advanced fibrosis, treatment-resistant patients, and any signs of decompensation
Direct hepatology referral is the right move for F4 (cirrhosis), confirmed or suspected, and for any patient with portal hypertension signs or hepatic decompensation

A real program builds and documents a hepatology referral pathway. That can be:

An in-network panel of hepatology partners in major states
A virtual hepatology consultation arrangement
A documented warm-handoff process for patients who cannot access in-network specialists

The provider note for a MASH patient should look like a chronic-disease note, not a weight loss visit. Diagnostic criteria, fibrosis staging evidence, treatment plan with explicit goals, follow-up cadence, escalation criteria.

For the broader provider model decision, see Provider Network vs. Your Own Clinicians: How DTC Telehealth Brands Should Choose.

What you can and cannot say in marketing

A MASH program has a real FDA indication. That means there is a path to honest, compliant claims that did not exist for off-label or compounded GLP-1 marketing.

What you can say:

That semaglutide is FDA-approved for MASH with moderate to advanced fibrosis in adults
That treatment is intended to reduce fibrosis and improve liver-related outcomes for eligible patients
That the program coordinates evaluation, labs, imaging, and provider review for patients with suspected MASH
That eligibility is based on clinical criteria and individual provider review

What you cannot say:

Implied promises of cirrhosis prevention, liver transplant avoidance, or extended life expectancy for individual patients
Claims that exceed the approved label (e.g., implying use in patients with F0 to F1 fibrosis when the indication is F2 to F3)
Comparative superiority claims against other therapies without substantiation
Off-label promotion (e.g., promoting unrelated indications under the MASH banner)
Outcome guarantees, even soft ones ("most patients see a fibrosis stage improvement in 12 months")

The clean line: claims tied to the labeled indication and provider judgment, not to numbers, comparisons, or guarantees. The state AG layer is increasingly active on health claims; for that context, see State AG Enforcement on AI Health Ads: What CT, NY, and CA Cases Mean for Telehealth Marketing.

For the platform-policy layer, see Meta and Google Ad Policy Changes for Healthcare in 2026.

Funnel, pricing, and channel

The decision that defines the program's identity: bolt MASH onto the existing weight loss funnel, or build it as a distinct condition program.

The case for keeping it bolted on:

Leverages existing GLP-1 supply chain and provider workflow
Captures patients who arrived for weight loss but qualify clinically for MASH
Shorter time to launch

The case for building it standalone:

Avoids confusing two distinct patient populations
Allows a different clinical narrative, different intake, different pricing
Builds a more defensible brand position for liver health
Better fit for partnerships with hepatology practices, lab networks, and imaging vendors
Cleaner ad accounts (a liver-health program faces less scrutiny than a weight loss program)

The cleanest answer for most operators is a separate program with its own landing experience and intake, sharing infrastructure underneath. The patient sees a coherent MASH offering; the operations team reuses the GLP-1 supply, lab, and pharmacy plumbing.

On pricing: MASH is a chronic-disease program with multiple touchpoints. The pricing model should be a true membership with labs, imaging coordination, and provider review baked in, not a one-time prescription. Subscription models that include the next FibroScan are differentiated and clinically defensible.

For the broader subscription design layer, see Subscription Design for Telehealth Programs: What Improves Retention and What Creates Churn.

Retention is a fibrosis story, not a weight story

Retention in MASH looks different from retention in weight loss.

A weight loss patient leaves when the scale stops moving. A MASH patient leaves when the program loses clinical coherence: a lab result they do not understand, a missed imaging appointment, a provider visit that felt transactional.

What keeps MASH patients engaged:

A clear baseline fibrosis stage and a visible roadmap
Lab and imaging milestones the patient can anticipate
Provider communication that ties the data to a clinical story
Education on what fibrosis stabilization and reversal mean in practical terms
A patient portal that surfaces trends (LFTs over time, FIB-4 over time, FibroScan results), not just bills

What loses MASH patients:

Generic weight loss content in their portal
Pricing surprises around imaging or specialty labs
Long gaps between lab results and provider explanation
A program that treats them like a weight loss customer

The MASH portal experience is a clinical dashboard with a billing layer on top, not a billing dashboard with a clinical note on top.

For the broader portal pattern, see Patient Portal Onboarding: The First 7 Days That Improve Retention in Telehealth and Telemedicine Patient Portal: Features Clinics Need for Booking, Messaging, Payments, and Refills.

What MASH means for adjacent programs

The MASH program does not exist in isolation. It interacts with what you already run.

Existing weight loss patients

A meaningful share of your current weight loss GLP-1 patients have undiagnosed fatty liver disease. The right move is not aggressive cross-sell; it is a clinical screen at intake or renewal, with optional FIB-4 calculation and a referral pathway for high-scorers.

A patient who arrived for weight loss and learns they have MASH may shift program identity. That is a retention win, not a cannibalization risk.

Type 2 diabetes patients

If your program touches type 2 diabetes (directly or as a weight loss comorbidity), MASH overlaps heavily. The lab data you already collect (HbA1c, lipids, sometimes LFTs) gives you most of the inputs for fibrosis scoring.

Longevity and metabolic-health programs

A MASH program slots cleanly into a longevity or metabolic-health platform. The clinical narrative (reverse metabolic dysfunction, protect organ function) aligns with longevity framing.

For the broader stack thinking, see The Longevity Stack: Combining NAD+, Peptides, GLP-1, and Rapamycin in One DTC Program and Low-Dose GLP-1 Beyond Weight Loss: Cardiac, Hepatic, and Metabolic Indications DTC Telehealth Should Track.

Implementation checklist

Use this when scoping a MASH program.

Clinical

Defined eligibility criteria mapped to the labeled indication (F2 to F3)
Intake captures metabolic risk factors, hepatic history, red flags
FIB-4 calculated automatically at intake
ELF or equivalent available for indeterminate cases
Imaging pathway documented per state
Hepatology referral panel built and active
Provider chart-note template aligned with chronic-disease management
Defined treatment, monitoring, and escalation criteria

Operations

Lab partner with the required panels at predictable pricing
Imaging vendor coverage by state, with patient-facing scheduling
Pharmacy partner with reliable supply of the approved drug for the labeled indication
Provider capacity planned around chronic-care visit cadence
Patient portal surfaces fibrosis trend, LFTs, FIB-4, imaging results

Commercial

Distinct program identity (landing page, intake, brand narrative) from weight loss
Membership pricing that reflects chronic-disease care
Marketing copy aligned to labeled indication and FTC standards
State-by-state availability accurate based on imaging access
Cross-program referral logic for weight loss and diabetes patients

Compliance

No claims that exceed the labeled indication
No outcome guarantees or comparative superiority claims
Affiliate and creator guidelines updated for the new program
State AG and platform-policy review on launch creative

For the broader operating dashboard pattern, see The Weekly Telehealth Ops Dashboard: 12 Metrics Leadership Should Actually Review.

Final takeaways

MASH is the first FDA-blessed chronic liver disease indication for a telehealth-prescribable GLP-1. That makes it a genuinely new program category, not a checkbox.

What to remember:

MASH is a liver disease, not a weight loss outcome. The program has to look and feel like chronic-disease care.
The patient population the indication actually targets is F2 to F3 fibrosis, not anyone with elevated liver enzymes.
The diagnostic workflow without biopsy is lab-based scoring (FIB-4, ELF) plus elastography. Imaging coordination is the part most operators underestimate.
The lab cadence is a chronic-disease cadence, not a one-time check.
The provider model needs internal medicine, endocrinology, or family medicine clinicians with a real hepatology referral pathway behind them.
Marketing has a clean compliant lane: stay inside the labeled indication, avoid guarantees, and stop short of comparative superiority claims.
The cleanest commercial answer is a standalone program sharing infrastructure with GLP-1 underneath, not a MASH module bolted onto a weight loss funnel.
Retention is built on a clinical story (fibrosis trend), not a body composition story (the scale).
MASH interacts with weight loss, type 2 diabetes, longevity, and metabolic-health programs. The right plays are screening and referral, not aggressive cross-sell.

The brands that build MASH well will treat it as the first of a wave of chronic-disease GLP-1 indications, not as a one-off product launch. Cardiac, renal, hepatic, and metabolic indications are the next decade of GLP-1 in DTC telehealth.

The operators who win those categories will be the ones whose clinical, lab, imaging, and care-coordination infrastructure was built like the patient was going to stay for years, because they are.